Key facts
- This page summarizes Daniel Joseph OConnell's Form 4 filing for Acumen Pharmaceuticals, Inc. (ABOS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Jan 2022, 15:20.
Daniel Joseph OConnell - 19 Jan 2022 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- ABOS
- Reported as of
- 19 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jan 2022, 15:20:08 UTC
- Prior SEC filing
- 02 Dec 2021
- Next SEC filing
- 18 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Katie Lapidus, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel Joseph OConnell filed Form 4 for Acumen Pharmaceuticals, Inc. (ABOS) on 21 Jan 2022.
Change
- Previous filing in this sequence was filed on 02 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABOS
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +455,000
- Change %
- Price
- $0.000000
- Shares after
- 455,000
- Date
- 19 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 455,000
- Exercise price
- $5.19
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on January 19, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest and become exercisable each month thereafter, subject to Reporting Person continuing to provide service through each such date.